Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of "Hold" from Brokerages

Certara, Inc. (NASDAQ:CERT - Get Free Report) has earned an average recommendation of "Hold" from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.6250.

CERT has been the subject of several research reports. Craig Hallum initiated coverage on shares of Certara in a research note on Monday, September 29th. They set a "buy" rating and a $16.00 price objective for the company. Weiss Ratings reissued a "sell (d)" rating on shares of Certara in a research note on Wednesday. KeyCorp boosted their price objective on shares of Certara from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday. UBS Group lowered their price objective on shares of Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, Barclays boosted their price objective on shares of Certara from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the transaction, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. The trade was a 40.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.33% of the company's stock.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Central Pacific Bank Trust Division acquired a new position in shares of Certara during the 3rd quarter valued at $86,000. Corient Private Wealth LLC lifted its holdings in shares of Certara by 11.1% during the 2nd quarter. Corient Private Wealth LLC now owns 12,299 shares of the company's stock valued at $144,000 after acquiring an additional 1,232 shares in the last quarter. Texas Permanent School Fund Corp lifted its holdings in shares of Certara by 44.5% during the 2nd quarter. Texas Permanent School Fund Corp now owns 86,019 shares of the company's stock valued at $1,006,000 after acquiring an additional 26,480 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Finally, Public Sector Pension Investment Board lifted its holdings in shares of Certara by 8.3% during the 2nd quarter. Public Sector Pension Investment Board now owns 376,100 shares of the company's stock valued at $4,400,000 after acquiring an additional 28,924 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Down 0.5%

CERT stock opened at $12.94 on Friday. The stock has a market capitalization of $2.08 billion, a P/E ratio of 258.85 and a beta of 1.45. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. Certara has a one year low of $8.64 and a one year high of $15.69. The company has a 50 day moving average price of $11.29 and a two-hundred day moving average price of $11.40.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The company had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same period in the prior year, the firm earned $0.07 earnings per share. The firm's quarterly revenue was up 12.1% on a year-over-year basis. As a group, sell-side analysts expect that Certara will post 0.28 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.